TABLE 4.

Liposomal formulations of anti-cancer drugs in phase III clinical trials

Product Name	Encapsulated Drugs	Type of Liposomes	Indications	Lipid Composition	Particle Size	Status	Reference
					nm
CPX-351	Cytarabine and daunorubicin (5:1)	Bilamellar liposomes	Acute myeloid leukemia	DSPC, DSPG and cholesterol	100	Phase III	NCT01696084a (accessed on Apr 14, 2015); Feldman et al. (2011); Cortes et al. (2015)
Lipoplatin	Cisplatin	PEGylated liposomes	NSCLC, gastric, pancreatic, breast, head and neck cancers	PC, cholesterol, DPPG, DSPE-PEG2000Da	110	Phase III	Boulikas (2009); Stathopoulos et al. (2010)
MM-398 (PEP02)	Irinotecan	PEGylated liposomes	Metastatic pancreatic cancer	DSPC, DSPE-PEG2000Da, cholesterol	100-110	Phase III	NCT01494506a (accessed on Apr 15, 2015); Drummond et al. (2006); Kang et al. (2015); Roy et al. (2013); Saif (2014)
Thermodox	Doxorubicin	Lyso-lipid temperature sensitive liposomes	Hepatocellular carcinoma and breast cancer	DPPC, MSPC, DSPE-PEG2000Da	175	Phase III	NCT00617981a (accessed on Apr 15, 2015); May and Li (2013)

^aClinicalTrials.gov identifier

DPPC, 1,2-dipalmitoyl phosphatidylcholine; DPPG, 1,2-dipalmitoyl phosphatidylglycerol; MSPC, mono-stearoyl phosphatidylcholine; NSCLC, non-small cell lung cancer